Tandem mass spectrometry of serum cholestanoic (C27) acids – Typical concentration ranges and application to the study of peroxisomal biogenesis disorders
Open Access
- 1 November 2024
- journal article
- research article
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 34, 34-43
Abstract
Primary bile acid synthesis is impaired in peroxisomal disorders, leading to the accumulation of long-chain bile acids, specifically dihydroxycholestanoic and trihydroxycholestanoic acids. Quantification of the diastereoisomers of these C27 bile acids is essential for the differential diagnosis of these disorders. High-performance liquid chromatography electrospray ionization-tandem mass spectrometry with stable-isotope dilution was used to quantify all eight diastereoisomers of cholestanoic acids in serum. Clinical ranges were established for patients with and without cholestatic liver disease, as well as for those with peroxisomal disorders. The assay was linear over the range of 20–2,500 ng/mL, and intra- and inter-assay imprecision was 10-fold higher (14.06 ± 2.59 μmol/L). Patients with heterozygous mutations in PEX genes had low concentrations of serum C27 bile acids. In all groups, the (25S)- and (25R)-diastereomers were present in a ratio of 0.3. In cases of 2-methylacyl-CoA racemase deficiency, serum total C27 bile acids were markedly elevated (10.61 ± 0.92 μmol/L) and comprised exclusively the (25R)-diastereoisomer. This tandem mass spectrometric assay quantifies all diastereoisomers of the C27 cholestanoic acids in serum and was used to establish typical clinical concentration ranges. The method is applicable to the diagnosis of peroxisomal disorders and differentiates 2-methylacyl-CoA racemase deficiency from other peroxisomal biogenesis disorders.Keywords
This publication has 36 references indexed in Scilit:
- The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapyJournal of Inherited Metabolic Disease, 2019
- Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthoodJournal of Inherited Metabolic Disease, 2015
- Incidental finding of alpha‐methylacyl‐CoA racemase deficiency in a patient with oculocutaneous albinism type 4American Journal of Medical Genetics Part A, 2012
- A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblastsJournal of Inherited Metabolic Disease, 2008
- Clinical, biochemical, and mutational spectrum of peroxisomal acyl–coenzyme A oxidase deficiencyHuman Mutation, 2007
- Bifunctional enzyme deficiency: Identification of a new type of peroxisomal disorder in a patient with an impairment in peroxisomal β‐oxidation of unknown aetiology by means of complementation analysisJournal of Inherited Metabolic Disease, 1992
- Oral bile acid treatment and the patient with zellweger syndromeHepatology, 1992
- The inborn errors of peroxisomal β‐oxidation: A reviewJournal of Inherited Metabolic Disease, 1989
- Plasma bile acids in patients with peroxisomal dysfunction syndromes: analysis by capillary gas chromatography — mass spectrometryEuropean Journal of Pediatrics, 1987
- Identification of 3α,7α,12α‐trihydroxy‐5β‐cholestan‐26‐oic acid, an intermediate in cholic acid synthesis, in the plasma of patients with infantile Refsum's diseaseJournal of Inherited Metabolic Disease, 1984